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Background: B7-H4 is a novel B7 ligand that plays an important role in the T cell-mediated immune response as a
negative regulator. Previous studies have suggested the aberrant expression of membrane B7-H4 in tumor cells. The
aim of this study is to determine the expression levels of preoperative soluble B7-H4 (sB7-H4) in circulation and to
investigate the correlations between sB7-H4 levels and clinicopathological parameters as well as the survival rate of
patients with gastric cancer.
Methods: Blood specimens from 132 patients with gastric cancer and 63 healthy volunteers were analyzed by
sandwich enzyme-linked immunosorbent assay.
Results: Median concentrations of sB7-H4 in patients with gastric cancer were significantly higher than those in
healthy volunteers (16.85 versus 10.46 ng/mL; P = 0.008). Median levels of sB7-H4 were significantly correlated with
tumor size, lymph node metastasis, the depth of tumor invasion and tumor-node-metastasis classification (P = 0.002,
P = 0.001, P = 0.041 and P <0.001, respectively), but not with sex, age, tumor location or histological subtype (all
P >0.05). Additionally, the overall survival rate was significantly lower in patients with high sB7-H4 levels when compared
with low sB7-H4 levels (50.0% versus 77.3%, χ 2 = 10.78, P = 0.001). Moreover, multivariate analysis demonstrated that the
risk of death was significantly higher in patients with high sB7-H4 levels than in those with low sB7-H4 levels (P = 0.039).
Conclusions: sB7-H4 is a valuable blood marker for predicting the progression and prognosis of patients with
gastric cancer.
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Gastric cancer is one of the most common types of can-
cer worldwide in terms of incidence and mortality [1],
especially in China [2]. Although multi-model treatment
strategies including surgery, perioperative chemotherapy,
radiotherapy and immunotherapy are used, the five-year
survival rate for patients suffering from gastric cancer is
still 25% or less [3-7]. Therefore, it is necessary to improve
current therapeutic modalities and to explore new bio-
logical molecular markers for predicting the progression
of gastric cancer and helping targeted therapy.* Correspondence: czsdyrmyyzlk@163.com; jjtnew@163.com
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family molecules may participate in the positive and
negative regulation of cell-mediated immunity in per-
ipheral tissues [8]. Recent findings have demonstrated
that B7-H1 (PD-L1), B7-H2 (PD-L2), B7-H3 and B7-H4
are aberrantly expressed in some tumor tissues and/or
sera of cancer patients, suggesting that these molecules
might be new molecular biomarkers for tumor diagnosis
and prognosis [9-11]. B7-H4 has been identified through
the National Center for Biotechnology Information
(NCBI) database searching and cDNA library screening
to reveal that its sequence contains B7 extracellular
immunoglobulin domains [12-14]. Previous studies have
showed that B7-H4 can regulate T cell-mediated immune
response through inhibiting T cell proliferation, cytokine. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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It has been reported that B7-H4 is expressed at high
levels in many cancer tissues such as breast, ovarian,
lung, pancreatic, renal cell and gastric cancers [10,20-27].
Simon et al. reported that B7-H4 is elevated in serum
samples from ovarian cancer patients when compared
with healthy controls or women with benign gynecological
diseases [10]. However, the clinical significance of B7-H4
expression in blood specimens from gastric cancer patients
has not yet been determined.
In this study, we examined circulating B7-H4 levels
in blood specimens from patients with gastric cancer
using an sandwich enzyme-linked immunosorbent assay
(ELISA) kit for soluble B7-H4 (sB7-H4). Additionally, we
investigated the correlation between sB7-H4 levels and
clinicopathological parameters, and patient survival rate.
Our results showed that the evaluation of sB7-H4 levels
could help for predicting the progression and prognosis of
patients with gastric cancer.Table 1 Correlation between sB7-H4 levels and clinical
characteristics of patients
Characteristics N Median (range) Z P
Sex 0.936 0.349
Male 97 15.76 (0.11-182.58)
Female 35 21.28 (1.86-171.31)
Age(years) 0.691 0.489
≥60 75 15.21 (0.11-182.58)
<60 57 18.28 (2.59-170.77)
Tumor location 1.363 0.506
Gastric cardia 21 25.26 (2.47-121.96)
Gastric body 54 14.97 (1.35-182.58)
Gastric antrum 57 17.82 (0.11-158.60)
Tumor size 3.12 0.002
<5 cm 85 13.96 (0.11-158.60)
≥5 cm 47 28.47 (1.35-182.58)
Lymph node metastasis 3.392 0.001
Negative 50 10.92 (0.11-144.97)
Positive 82 21.32 (1.35-182.58)
Depth of tumor invasion 2.039 0.041
pT1-T2 35 12.22 (1.51-109.66)
pT3-T4 97 19.65 (0.11-182.58)
Histology differentiation 1.045 0.296
Differentiated 67 18.28 (1.35-171.31)
Poorly differentiated 65 15.16 (0.11-182.58)
Stage 3.524 <0.001
I + II 69 12.22 (0.11-144.97)
III + IV 63 22.72 (1.35-182.58)Methods
Selection of patients
Blood specimens were preoperatively collected from 132
primary gastric cancer patients (97 men and 35 women;
age range 30 to 86-years-old; average age 61.39-years-
old) treated surgically at the Third Affiliated Hospital of
Soochow University (Jiangsu Province, China) between
2008 and 2010. Patients who had undergone any form of
preoperative chemotherapy and/or radiation therapy were
excluded. Furthermore, none of patients enrolled in this
study suffered from other cancers. Each patient with
gastric cancer was classified on the basis of the tumor-
node-metastasis (TNM) classification of the International
Union against Cancer (UICC) [28]. Peripheral blood speci-
mens from 63 healthy volunteers (39 men and 24 women;
age range 25 to 87-years old; average age 48.91-years-old)
who had never received a diagnosis of malignancy were
chosen as the control group. The remaining clinical and
pathological features are shown in Table 1. Collected sam-
ples were kept at room temperature (RT) for a minimum
of 30 minutes (and a maximum of 60 minutes), and serum
was obtained after centrifugation at 4000 rpm at 4°C for
10 minutes. The serum was immediately removed and
frozen on dry ice at −80°C until use.
Before enrollment this study protocol was approved by
the ethics committee of Soochow University and this
study was conducted in accordance with the principles
of the Declaration of Helsinki and Good Clinical Prac-
tice Guidelines. Patients and healthy volunteers provided
written informed consent for all specimens collected.Figure 1 Sandwich ELISA analysis for sB7-H4 levels in blood
specimens. Median concentration of sB7-H4 in patients with
gastric cancer was significantly higher than those in healthy volunteers
(P= 0.008).
Figure 2 All patients were divided into low (n = 66) and high
(n = 66) sB7-H4 level groups. Survival curves were analyzed by
Kaplan-Meier method and log-rank test. Patients with high sB7-H4
levels had a significantly poorer survival rate when compared to
those with low sB7-H4 levels (P = 0.001).
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Simon et al. have developed a sensitive sandwich ELISA
to analyze the expression level of sB7-H4 in serum sam-
ples from patients with ovarian cancer [10]. A similar
protocol was used for the blood specimens from patients
with gastric cancer and the healthy volunteers. Briefly,
25 μL of the undiluted blood specimen was added to
high-binding polystyrene plates coated with capture mAb
Clone H74 (eBioscience, San Diego, United States). Immo-
bilized antigen was detected with diluted biotinylated
secondary mAb (eBioscience, San Diego, United States)
followed by horseradish peroxidase-conjugated streptavidin
(Biolegend Inc., Californian, United States). For calibration,
the standards of recombinant protein and two controls
were conducted in parallel with the test samples on
each plate.
Statistical analysis
Due to non-normal distribution, differences between the







sB7-H4 expression High/Low 2.677(1.452-4.934
Gender Male/Female 1.153(0.618-2.148
Age <60/≥60 0.988(0.962-1.015
Tumor size <5 cm/≥5 cm 2.714(1.536-4.794
Lymph node metastasis Positive/Negative 5.792(2.458-13.64
Depth of tumor invasion pT3-T4/pT1-T2 2.714(1.536-4.794
TNM stage III,IV/I,II 5.966(2.962-12.01test. Survival time was calculated from the first day of
diagnosis to the date of last follow-up or death, and the
median follow-up period after diagnosis was 35 months
(range, 1 to 61 months). Survival curves were analyzed
using Kaplan-Meier curves and differences in survival
rates were examined using the log-rank test. Univariate
and multivariate analyses (Cox proportional hazards re-
gression model) were performed to evaluate the progno-
sis factors for gastric cancer. All statistical analyses were
performed using the Statistical Package for the Social
Sciences, version 13.0 (SPSS, Chicago, Illinois, United
States). A statistically significant difference was consid-
ered to be a P value less than 0.05.Results
Analysis of sB7-H4 in gastric cancer patients versus
healthy controls
Sandwich ELISA was used to assay the levels of sB7-H4
in serum samples from 132 patients with gastric cancer
and 63 healthy volunteers. As shown in Figure 1, an ele-
vated level (median) of sB7-H4 in serum samples from
patients with gastric cancer (16.85 ng/mL with a range
of 0.11 to 182.58 ng/mL) was observed when compared
with that from healthy volunteers (10.46 ng/mL with a
range of 0.47 to 43.23 ng/mL; P = 0.008).Relationship between sB7-H4 expression and
clinicopathological factors in patients with gastric cancer
With the extension of tumors, the sB7-H4 levels tended
to increase in blood specimens from gastric cancer
patients. As shown in Table 1, the median sB7-H4 level
was significantly higher in gastric cancer patients with
tumor size of more than or equal to 5 cm than in
patients with tumor size of less than 5 cm (P = 0.002).
Patients with lymph node metastasis had higher sB7-H4
levels when compared with those without lymph node
metastasis (P = 0.001). In addition, sB7-H4 levels revealed
an enhancement with the depth increase of tumor invasion
and TNM stage (P = 0.041 and P <0.001, respectively).
However, no statistically significant correlation betweenal in patients
riate analysis Multivariate analysis
5% CI) P value Hazard ratio (95% CI) P value
) 0.002 1.925(1.033-3.857) 0.039
) 0.655 1.194(0.772-1.873) 0.497
) 0.393 1.014(0.529-1.384) 0.859
) 0.001 1.008(0.284-1.637) 0.359
4) <0.001 1.623(0.633-2.365) 0.195
) 0.001 1.842(0.825-1.972) 0.156
3) <0.001 5.184(2.544-10.563) <0.001
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subtype was observed (P = 0.349, P = 0.489, P = 0.506 and
P = 0.296, respectively).
Relationship between sB7-H4 expression and prognosis
Based on the median value of sB7-H4 levels, we used
16.85 ng/mL as the cutoff value to divide all patients
into groups with low (n = 66) and high (n = 66) sB7-H4
levels. The overall survival rates of patients with low and
high levels of B7-H4 were 77.3 and 50.0%, respectively
(Figure 2) (χ 2 = 10.78, P = 0.001). As shown in Table 2,
univariate analysis showed that tumor size, lymph node
metastasis, depth of tumor invasion, TNM stage and
sB7-H4 expression were significantly related to overall
survival (P = 0.001, P <0.001, P = 0.001, P <0.001 and
P = 0.002, respectively). Multivariate analysis indicated
that the death risk of gastric cancer patients in the high
B7-H4 level group was significantly higher (P = 0.039).
As expected, the higher TNM stage was also significantly
associated with an elevated risk of death for gastric
patients (P <0.001).
Discussion
B7-H4 is a member of B7 family which inhibits tumor-
specific T cell-mediated immune response [29]. Previous
studies have showed that the expression levels of B7-H4
were significantly higher in many cancerous cells of
gastric cancer tissues than that in the gastric polyp
tissues or adjacent normal tissues [19]. In the present
study, we quantitatively measured the expression levels
of sB7-H4 in serum samples from patients with gastric
cancer and healthy volunteers by sandwich ELISA.
Compared with the level of sB7-H4 in healthy volunteers,
sB7-H4 level was significantly increased in patients with
gastric cancer. Additionally, sB7-H4 was detected in blood
samples from patients with renal cell carcinoma and ovar-
ian cancer according to ELISA assays [10,30]. Therefore,
sB7-H4 is not specific to gastric cancer and might serve as
a potential serum biomarker of various malignancies.
We have found that sB7-H4 is significantly correlated
with tumor size, lymph node metastasis, depth of tumor
invasion and TNM stage, indicating that sB7-H4 may be
a valuable marker for predicting tumor progression in
patients with gastric cancer. In fact, Arigami et al. [31]
have found that B7-H4 mRNA copies in patients with
gastric cancer are significantly correlated with the depth
of tumor invasion, lymph node metastasis and overall
stage through quantitative reverse transcription polymerase
chain reaction (RT-PCR) analysis. In addition, the five-year
survival rate of B7-H4-positive patients was lower than
that of B7-H4-negative patients [31]. The present study
exhibited a correlation between the sB7-H4 level and
survival rate of patients with gastric cancer. Moreover,
the multivariate analysis confirmed that sB7-H4 was anindependent factor for affecting the survival time of
gastric cancer patients. These results indicated that the
assessment of sB7-H4 levels in blood might help for
predicting the prognosis of patients with gastric cancer
and establishing treatment strategies.
B7-H4 may contribute to the immune system during
tumor progression. Some reports have demonstrated
that B7-H4 can inhibit CD4 and CD8-positive T lympho-
cyte proliferation, cell-cycle progression, the production of
interleukin (IL)-2, IL-4 and IL-10 and antitumor immunity
[12-14]. The overexpression of sB7-H4 in blood from
gastric cancer patients may promote tumor progression
by providing the mechanism for cancer cells to avoid
immune attack. Our study suggests that the blockade
of B7-H4 may be beneficial for the enhancement of
immunological function and the prognosis of gastric
cancer patients.
Conclusions
We have demonstrated that sB7-H4 is a promising serum
biomarker that may help to improve progression and
prognostic assessment of gastric cancer. Furthermore,
B7-H4 inhibition may be a useful method for treating
gastric cancer. However, further studies are needed to
explore the potential role of monitoring cancer cells in
patients after surgery and chemotherapy.
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